1068 results about "Extracellular" patented technology

The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure thereof and exhibits higher effector activity such as an antibody-dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient. In addition, the present invention provides an anti-human TIM-3 antibody having high ADCC activity by screening an anti-human TIM-3 antibody which competes with the monoclonal antibody or the antibody fragment thereof.

The present invention relates to an apparatus and a method for sealing a puncture in a tubular tissue structure or the wall of a body cavity. More specifically, the present invention is directed to an apparatus and method for sealing a puncture site in the wall of a tubular tissue structure, or in the wall of a body cavity with a bioabsorbable material such as submucosal tissue, another extracellular or matrix-derived tissue, or a synthetic material capable of remodeling endogenous connective tissue in vivo. The bioabsorbable material is inserted into the puncture site as a sheet on an introducer element used to access the lumen of a tubular tissue structure or used to access a body cavity.

The invention provides human extracellular adhesive proteins (EXADH) and polynucleotides which identify and encode EXADH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EXADH.

A redirected Treg cell is endowed with specificity toward a selected target antigen or ligand. The cell contains a chimeric receptor polypeptide that is expressed in a single, continuous chain, with an extracellular recognition region displayed on the surface of the cell, a transmembrane region and an intracellular signaling region. The extracellular recognition region is specific for the selected target antigen or ligand. The intracellular signaling region includes a combination of T-cell signaling polypeptide moieties, which combination, upon binding of the extracellular recognition region to the selected target antigen or ligand, triggers activation of the redirected Treg cells to cause suppression of T-cell mediated immunity. Such redirected Treg cells may be used to suppress undesired activity of T effector cells thereby mediating an immune or inflammatory response. They are particularly useful in treating T effector cell-mediated diseases, such as inflammatory bowel disease, transplant rejection and GVH disease.

Apparatus and method for processing specimens, e.g., biological specimens, to extract samples for both liquid (i.e., extracellular) and slide-based (i.e., intracellular) testing. Both types of samples can be obtained from a single fluid specimen. A fluid sampling station removes fluid from a specimen container and places it in a sample receptacle. A specimen acquisition station removes fluid from the container, separates particulate matter (e.g., cells) from the removed fluid, and forms a sample layer of particulate matter, which is transferred to a slide. The two sampling operations can be carried out in any order. The fluid sample receptacle may have a special one-way valve arrangement. The apparatus can be automated so as to process multiple fluid specimens in their respective containers. The machine according to this invention is a "platform instrument" that can produce all required liquid samples and slide-based samples for essentially all cytopathology tests.

Fibroblast growth factor receptor (FGFR) extracellular domain (ECD) acidic region muteins that have been engineered to exhibit decreased tissue binding by increasing the number of acidic amino acid residues within the D1-D2 linker region are provided. Polynucleotides encoding FGFR ECD acidic region muteins are also provided. Methods of making FGFR ECD acidic region muteins, and methods of using such molecules to treat proliferative disorders, including cancers, disorders of angiogenesis, and macular degeneration, are also provided.

A wastewater treatment process having improved solids separation characteristics and reduced biochemical oxygen demand (BOD) in the purified wastewater comprising the steps of: passing wastewater through a main aerobic biological oxidation zone and therein oxidizing a portion of the BOD a portion of the ammonia nitrogen content (NH3-N); passing the effluent from said aerobic biological oxidation zone to an aerobic/mixing zone and therein mixing said effluent with effluent from the anoxic/anaerobic zone; passing the effluent from said aerobic/mixing zone to a settling zone and therein separating purified wastewater having reduced BOD and suspended solids, and sludge containing suspended solids; passing a portion of the sludge formed in the settling zone and volatile acids to an anoxic/anaerobic zone and therein increasing the extracellular polymer content of said sludge, the release of phosphorus into solution and the reduction of nitrate nitrogen to molecular nitrogen gas; and recycling an effective amount of the effluent from said anoxic/anaerobic zone to said aerobic/mixing zone. In an alternative embodiment, a volatile acid is added to a zone to which no additional oxygen has been added that is in the flow path from the main aerobic biological oxidation zone or, alternatively, it may be added to the anoxic/anaerobic zone and the thus-treated effluent is passed to the aerobic/mixing zone wherein phosphate is removed from the effluent.

A single chain T cell receptor (scTCR) comprising an a segment constituted by a TCR α chain variable region sequence fused to the N terminus of a TCR α chain constant region extracellular sequence, a β segment constituted by a TCR β chain variable region fused to the N terminus of a TCR β chain constant region extracellular sequence, and a linker sequence linking the C terminus of the a segment to the N terminus of the β segment, or vice versa, the constant region extracellular sequences of the α and β segments being linked by a disulfide bond, the length of the linker sequence and the position of the disulfide bond being such that the variable region sequences of the α and β segments are mutually orientated substantially as in native αβ T cell receptors. Complexes of two or more such scTCRs, and use of the scTCRs in therapy and in various screening applications are also disclosed.

A device and method are provided for determining the volume ECV_hydr(t) of a body compartment of a patient at a time t by conducting measurements at the time t of the patient to determine at least one anthropometric measure X(t), the extracellular water volume ECV(t), and the intracellular water volume ICV (t) of the patient. The extracellular water volume ECV_basic(t) of a first compartment with weight W_basic(t) of the patient at the time t is derived by using X (t), the extracellular water volume ECV_sec(t) of a second compartment of the patient at the time t is derived by using ICV (t), and ECV_hydr(t) as the extracellular water volume of a third compartment of the patient is derived with weight W_hydr(t). The extracellular volume ECV_hydr(t) is a measure for the hydration status of the patient.

Soluble polypeptide fraction consisting of all or part .[.one.]. .Iadd.of .Iaddend.at least .Iadd.one .Iaddend.of the four immunoglobulin-type extracellular LAG-3 protein domains (amino acids 1-159, 160-.[.230.]. .Iadd.239.Iaddend., 240-330 and 331-412 of the SEQ ID NO:1 sequence) or consisting of one peptide sequence derived from these domains by replacement, addition or deletion of one or more amino acids. The fraction of the invention has a specificity at least equal to that of LAG-3 in relation to its ligand.

The present invention relates to specific CSF1R ECD fusion molecules that exhibit improved therapeutic properties. The invention also relates to polypeptide and polynucleotide sequences, vectors, host cells, and compositions comprising or encoding such molecules. The invention also relates to methods of making and using the CSF1R ECD fusion molecules. The invention further relates to methods of treatment using the CSF1R ECD fusion molecules. For example, certain CSF1R ECDs of the invention may be used to treat rheumatoid arthritis (RA) or multiple sclerosis (MS).

The present disclosure provides a novel mutant strain of Schizochytrium limacinum having the Accession No. MTCC 5249, which produces lipids and extracellular polysaccharide (EPS) simultaneously. The disclosure further provides a process for simultaneous production of lipids and extracellular polysaccharide (EPS) from the novel mutant strain of Schizochytrium limacinum. The lipids produced from the novel mutant strain of Schizochytrium limacinum comprises docosahexaenoic acid (DHA). The disclosure also provides a food, feed, cosmetic, nutritional or therapeutic supplement for humans or animals comprising the cell biomass and extracellular polysaccharides (EPS) of the mutant strain of Schizochytrium limacinum. A cosmetic composition comprising the extracellular polysaccharides (EPS) of Schizochytrium limacinum is also provided that is useful as a base for cosmetics for topical application. The present disclosure further provides a pickle composition and a fat product having improved nutritive value.

The present invention describes inhibitors of extracellular Hsp90. The inhibition of extracellular Hsp90 leads to a reduction of the invasiveness of the tumor cells. Furthermore, the invention relates to the use of molecules inhibiting extracellular Hsp90 function for the manufacture of a medicament for the treatment or prevention of invasion and/or metastatic potential of cancer cells.

The present invention relates to a method to engineer immune cell for immunotherapy. In particular said immune cells are engineered with chimeric antigen receptors, which be activated by the combination of hypoxia and ligand extracellular binding as input signals. The invention also relates to new designed chimeric antigen receptors which are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties and the hypoxia condition. The present invention also relates to cells obtained by the present method, in particular T-cells, comprising said chimeric antigen receptors for use in cancer treatments.

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.